-

Agilent Announces Gen6 Software for BioTek Line of Microplate Readers

New capabilities offer simplicity and walkup usability for multimode detection

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of new Gen6 software for all Agilent BioTek detection instruments. Featuring a broad range of prebuilt experiment templates for common applications, the new software provides automated optimization tools and improved navigation through built-in data analysis functions.

Modern laboratories house an array of sophisticated analytical instruments controlled by equally sophisticated – and often formidably complex – software. Straightforward instrument control interfaces that quickly and reliably connect users to essential results can significantly increase the speed and ease with which scientific research efforts move forward.

The design of the Agilent BioTek Gen6 software facilitates ‘walkup’ convenience for all users, regardless of experience level. The software also features an intuitive user interface that enables complete control of BioTek microplate readers for absorbance, fluorescence, and luminescence measurements in a variety of microplates for both endpoint and kinetic assays. Reading parameters, plate layout, and data analysis definition are easily established through a step-by-step process for both quantitative and qualitative assays. Additionally, well data and analysis results can be exported automatically or fully customized to suit data reporting requirements.

“The new Gen6 software for Agilent BioTek microplate readers delivers an improved user experience," said Caleb Foster, associate vice president of marketing for Agilent's Cell Analysis Division. “Agilent continues to develop innovative new plate readers to support our customers’ needs, driven by extensive user feedback. Gen6 is next-generation software providing new and seasoned users with the tools required for existing and future applications.”

Gen6 software is standard on all new Agilent BioTek microplate readers; existing users of Gen5 software can purchase an upgrade to Gen6.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

MEDIA CONTACT
Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com

AGILENT TECHNOLOGIES INC

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

MEDIA CONTACT
Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com

More News From AGILENT TECHNOLOGIES INC

Agilent Receives European IVDR Certification for Companion Diagnostic Assay in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the use as a Companion Diagnostic (CDx) to aid in the identification of gastric or gastroesophageal Junction (GEJ) adenocarcinoma patients who may be eligible for treatment with KEYTRUDA® (pembrolizumab)1. PD-L1 IHC 22C3 pharmDx (Code SK006) is approved for exclusive use with the Agilent Autostainer Link 48 advanced...

Agilent to Announce Second-Quarter Fiscal Year 2025 Financial Results on May 28

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release financial results for the second quarter of fiscal year 2025 after the stock market closes on Wednesday, May 28. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PDT on the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent’s investor relations website. A recording of the call also will be available on the website...

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ FDA approval for AUCATZYL®, a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the xCELLigence Real-Time Cell Analysis (RTCA) technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise a...
Back to Newsroom
  1. There was an issue with the authorization server. Please contact support if the issue persists.